Psoriatic Arthritis

Among patients with psoriatic arthritis, a 36-item Short Form Health Survey was the best predictor of progression from oligoarticular to polyarticular arthritis.

Patient-reported outcomes, in addition to physician assessment, suggest apremilast improves quality of life and symptoms of psoriatic arthritis within 6 months.

“As the therapeutic landscape for PsA evolves, evaluating the long-term safety of treatments is essential to understand benefit–risk profiles and inform patient care,” investigators explained.

Ana-Maria Orbai, MD, MHS, leads the discussion on a real-world case scenario of a 57-year-old man who presents with severe plaque psoriasis and arthritis and shares clinical impressions as well as therapeutic goals for the patient.

Sheetal Desai, MD, leads the discussion on a real-world case scenario of a 26-year-old woman with polyarticular symmetric psoriatic arthritis and shares her approach to treatment.

Novartis receives approval for Cosentyx, their biologic treatment for enthesitis-related arthritis and juvenile psoriatic arthritis, in children and adolescents.

Louis Bessette, MD, MSc, explains the impact of early pain improvement on patient-reported outcomes in patients with psoriatic arthritis.

Leonard H. Calabrese, DO, leads the discussion on a real-world case-based scenario of a 31-year-old woman with psoriatic arthritis and shares clinical impressions.

Ana-Maria Orbai, MD, MHS; Anthony M. Turkiewicz, MD; Leonard H. Calabrese, DO; and Sheetal Desai, MD, comment on the appropriate circumstances to switch therapies for the management of psoriatic arthritis.

The US FDA approved upadacitinib (15 mg daily) for the treatment of adults with active psoriatic arthritis with inadequate response to at least 1 TNF blocker.

Ana-Maria Orbai, MD, MHS, comments on the safety and efficacy of TNF-alpha inhibitors for the management of psoriatic arthritis and Anthony M. Turkiewicz, MD, reviews the phase 3 FUTURE trials.

Sheetal Desai, MD, reviews the MOAs of currently available biologics for the management of psoriatic arthritis.

Leonard H. Calabrese, DO, shares insight on goals of therapy and factors that guide treatment selection for patients with psoriatic arthritis.

Previous studies examining whether inflammatory disease was associated with an increased risk of Alzheimer's disease yielded mixed results.

Guselkumab is the first and only selective interleukin inhibitor therapy in the US that's approved for both moderate-severe plaque psoriasis and active psoriatic arthritis regardless of prior TNFi exposure.

Philip Mease, MD, explains the recent Phase 3 data from the DISCOVER-1 and DISCOVER-2 clinical trials which demonstrated guselkumab inhibited radiographic progression, and improved symptoms and pain in patients with active psoriatic arthritis (PsA).

A correlation between disease activity and overall hand functionality was discovered in patients with psoriatic arthritis.

Anthony M. Turkiewicz, MD, leads the discussion on diagnosing psoriatic arthritis (PsA), including differentiating PsA from axial spondyloarthritis, and comments on the role of CASPAR criteria in clinical practice.

Sheetal Desai, MD, leads the discussion on the typical presentation of psoriatic arthritis, common comorbidities associated with the disease, and the importance of an early and accurate diagnosis.

Louis Bessette, MD, MSc, explains the impact of early pain improvement on patient-reported outcomes in patients with psoriatic arthritis.

Ana-Maria Orbai, MD, FACR, MHS, explains how guselkumab improved PROMIS-29 scores in patients with psoriatic arthritis.

Soumya Chakravarty, MD, PhD, discusses the unmet patient needs in immune-mediated diseases and Janssen’s role in scientific innovation that allows patients to live their lives unburdened by disease.

Leonard H. Calabrese, DO; Sheetal Desai, MD; and Ana-Maria Orbai, MD, MHS, discuss the impact of psoriatic arthritis on a patient’s quality of life [QoL] and describe tools for measuring QoL.

Leonard H. Calabrese, DO, provides insight on the pathophysiology of psoriatic arthritis [PsA].

The biologic has shown promise in the management of both plaque psoriasis and psoriatic arthritis.